The Conscious Fund

The Conscious Fund is a venture capital firm focused on investing in early-stage companies within the emerging psychedelic medicine space. Founded with a mission to support the development of innovative solutions for mental health, addiction, and chronic pain, the fund identifies and backs pioneering startups in life sciences, healthtech, and therapeutic development. The Conscious Fund has a diverse portfolio, including companies such as ATAI Life Sciences, Cybin, and Wesana Health, all of which are working on groundbreaking treatments for mental health disorders using psychedelic substances like psilocybin and MDMA. The fund's strategy involves investing at both the seed and post-IPO stages, with a focus on companies that have strong, balanced leadership teams and clear paths toward regulatory approval and commercialization. As psychedelic therapies gain greater acceptance and continue to show promise in clinical trials, The Conscious Fund aims to be at the forefront of this growing industry, supporting its portfolio companies through expertise, capital, and a global network of co-investors. Notably, The Conscious Fund is responsible for helping several companies go public, including Albert Labs and ATAI Life Sciences, highlighting its commitment to bringing these new therapeutic approaches to broader markets. As the psychedelic medicine industry continues to expand, The Conscious Fund is well-positioned to play a pivotal role in shaping the future of mental health treatment.